Year-end Sale % OFF 
Abstract
Highlights: 1. There was no relationship between total lymphocyte count and antibody titers against SARS-CoV-2.2. This original research report offers information on the several blood test result after getting COVID-19vaccines and provides data that the public may use as scientific evidence to the further research. Abstract SARS-CoV-2 is a virus that infects the respiratory tract and attacks the respiratory mucosa and epithelial cells.Lymphocytes are a subset of agranulocyte leukocytes that have a role in the immune response to pathogenicmicroorganisms' attacks. The number of lymphocytes will increase if a virus causes an infection. An antibody is aprotective protein produced by the body's immune system in response to the presence of an antigen. Antibodies bind and inactivate foreign substances so that the replication of pathogens can be prevented and destroyed. This mechanism can be expressed through the total number of lymphocyte cells. The objective of this study was to define the relationship between the number of lymphocytes and antibody titers against SARS-CoV-2. The type of research used was analytic observational with a cross-sectional approach using quantitative analysis methods and a purposive sampling method for sampling. The samples used were 30 donor blood samples from UTD PMI Surabaya. This research was conducted in May 2022 at the Hematology Laboratory, Department of Medical Laboratory Technology, Poltekkes, Ministry of Health, Surabaya, to examine the number of lymphocyte cells using the flowcytometry method and the Immunoserology Laboratory of the Surabaya Health Laboratory Center for antibody titer examination using the ELISA (Enzyme-Linked Immuno Sorbent Assay) method. The study showed an average lymphocyte level of 2.2633 x 103/µl and an average antibody titer value expressed in OD of 0.2197. Data analysis using Spearman's rank correlation statistical test revealed p = 0.262 0.005. It showed no relationship between total lymphocyte count and antibody titers against SARS-CoV-2
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
